Clinical Trial Update: Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating intraperitoneal aerosolized nanoliposomal irinotecan (Nal-IRI) for peritoneal carcinomatosis from gastrointestinal cancers. Recruitment…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Appendiceal Cancer
• Cholangiocarcinoma
• Colorectal Cancer
• Gastric Cancer
• Pancreatic Cancer
• Peritoneal Carcinomatosis
• Peritoneal Metastasis
• Small Bowel Cancer

Drugs mentioned

• Nal-IRI (Nanoliposomal irinotecan) (nanoliposomal irinotecan)

Snippet

Sponsor: University Hospital, Ghent | Conditions: Peritoneal Carcinomatosis, Peritoneal Metastases | Phase 1 | Status: RECRUITING